
Jyoti Nangalia
@jyoti_nangalia
Blood cancer, clonal evolution and ageing | Discovered CALR mutations in MPN | Group leader @sangerinstitute and @SCICambridge | Haematologist @CUH_NHS
ID: 710520006841409536
https://scholar.google.com/citations?user=MVXPtg4AAAAJ&hl=en&oi=ao 17-03-2016 17:35:45
505 Tweet
1,1K Followers
327 Following




Thrilled to share new work led by Jie Yang in the lab published today in nature. We find that Aspirin prevents metastasis by releasing T cells from immune suppression by platelet TXA2. Cambridge University CRUK Cambridge Centre rdcu.be/eci1U


Congrats Chiraag Kapadia - your hard work paid off. Was great having you in the team - you’ve got the genomics bug now! 🧬

Out today in Nature Medicine phase 3 data from thh MANIFEST-2 study nature.com/articles/s4159… Stephen Oh Andrew Kuykendall MD Prithviraj Bose Claire Harrison Ruben A. Mesa, MD Vikas Gupta Thread below


Excited to share our exploration Nature Methods into new horizons opening up in the era of low cost sequencing! 🔥 Deeper sequencing at WGS scale for PPM sensitivity of tumor informed MRD 🔥Duplex sequencing at WGS scale for plasma only exploration of ctDNA Check out thread 👇

It took three extraordinary, tenacious Scottish women with an army behind them to get this case heard by the Supreme Court and, in winning, they’ve protected the rights of women and girls across the UK. For Women Scotland, I’m so proud to know you 🏴💜🏴💚🏴🤍🏴



So proud of Jean Abraham and her team for this study that is all over the news today! Catch the BBC1 coverage of these amazing clinical trial results for patients with BRCA positive breast cancer. Thank you for all you do for patients! CRUK Cambridge Centre: Breast Cancer


Excited to share with all our latest work on the use of single cell tools in following IDH mutant AML patients during their treatment! Out today Cell Stem Cell !! An amazing collaboration with AK Eisfeld & Elli Papaemmanuil, PhD & Dan Landau !!! Driven by the impressive Maria Sirenko



"We hope such genomic data will guide the optimisation of future treatment plans to deliver effective chemotherapies with much fewer damaging side effects for patients.” – Dr Jyoti Nangalia, Wellcome Sanger Institute
